drugset / Trial / NCT02689518
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Phase 4
Completed
50 enrolled
University of California, San Diego
Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
Timeline
- Start
- 2014-04
- Primary completion
- 2019-11-12
- Completion
- 2019-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |